Dr. Shengmin Sang has received another patent for compounds comprising aspirin and ginger derivatives that have shown promise for preventing and treating cancer. This patent supplements a patent Sang received in 2015 for other novel aspirin-derived compounds. “N.C. A&T is working with Dr. Sang to build a robust patent portfolio around this ground-breaking research, and we are delighted by this most recent recognition,” says Dr. Laura Collins, director of intellectual property development within A&T’s Division of Research and Economic Development.
Combining aspirin and ginger derivatives with anti-cancer properties, the newly patented compounds are more effective than their individual components in killing colon cancer cells in laboratory tests. The compounds are prodrugs, which become pharmacologically active when they are metabolized. In addition to their anti-cancer properties, the new ginger-based derivatives have the potential to reduce the irritation of the digestive system frequently caused by aspirin. If the compounds can lessen those adverse side effects, more patients could benefit from aspirin’s ability to prevent or treat colon cancer, heart disease and other disorders.